Cargando…

Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study

BACKGROUND: The introductions of anti‐ human epidermal growth factor receptor‐2 (HER2) agents have significantly improved the treatment outcome of patients with HER2‐positive breast cancer. BAT8001 is a novel antibody‐drug conjugate targeting human epidermal growth factor receptor‐2 (HER2)‐expressin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Ruoxi, Xia, Wen, Wang, Liye, Lee, Kaping, Lu, Qianyi, Jiang, Kuikui, Li, Shengfeng, Yu, Jinquan, Wei, Jin, Tang, Weijia, Zhou, Danyang, An, Xin, Huang, Jiajia, Xue, Cong, Bi, Xiwen, Shi, Yanxia, Yuan, Zhongyu, Xu, Fei, Wang, Shusen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896747/ https://www.ncbi.nlm.nih.gov/pubmed/33528890 http://dx.doi.org/10.1002/cac2.12135

Ejemplares similares

Miller–Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant Chemotherapy
por: Wang, Liye, et al.
Publicado: (2021)

Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
por: Duan, Fangfang, et al.
Publicado: (2021)

Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center
por: Lu, Qianyi, et al.
Publicado: (2020)

Local treatment for liver oligometastases in breast cancer patients: identification of prognostic factors and exploration of appropriate treatment strategy
por: Jiang, Kuikui, et al.
Publicado: (2020)

Current Situation of Diagnosis and Treatment of HER2-Positive Metastatic Breast Cancer Patients in China: A Nationwide Cross-Sectional Survey of Doctors
por: Jiang, Kuikui, et al.
Publicado: (2023)

The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer
por: Zhou, Danyang, et al.
Publicado: (2023)

Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population
por: Wang, Liye, et al.
Publicado: (2021)

Identification and characterization of critical genes associated with tamoxifen resistance in breast cancer
por: Zhang, Kai, et al.
Publicado: (2020)

Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor‐Positive/Androgen Receptor‐Positive Advanced Breast Cancer
por: Lu, Qianyi, et al.
Publicado: (2019)

Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
por: Jiang, Kuikui, et al.
Publicado: (2023)

Significant response to margetuximab in Chinese HER2-positive metastatic breast cancer patient who progressed after second-line targeted therapy
por: Li, Jiaping, et al.
Publicado: (2023)

Distribution Characteristics and Prognostic Value of Immune Infiltration in Oligometastatic Breast Cancer
por: Zhou, Danyang, et al.
Publicado: (2021)

The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005)
por: Duan, Fangfang, et al.
Publicado: (2022)

Systemic Therapy Combined with Locoregional Therapy Improved Survival in Oligometastatic Breast Cancer: A Single-Center Retrospective Cohort Study
por: Ma, Yuyu, et al.
Publicado: (2022)

Administration of Lapatinib with Food Increases Its Plasma Concentration in Chinese Patients with Metastatic Breast Cancer: A Prospective Phase II Study
por: Xu, Fei, et al.
Publicado: (2020)

What is the appropriate genetic testing criteria for breast cancer in the Chinese population?—Analysis of genetic and clinical features from a single cancer center database
por: Ni, Mengqian, et al.
Publicado: (2023)

CPSF4 promotes triple negative breast cancer metastasis by upregulating MDM4
por: Lee, Kaping, et al.
Publicado: (2021)

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
por: Qin, Tao, et al.
Publicado: (2013)

The prognostic significance of skin involvement in breast cancer patients with chest wall recurrence
por: Zhou, Danyang, et al.
Publicado: (2023)

Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis
por: Zhang, Kai, et al.
Publicado: (2018)

Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1
por: Qi, Rongbin, et al.
Publicado: (2023)

Construction and validation of a macrophage polarization-related prognostic index to predict the overall survival in patients with early-stage triple-negative breast cancer
por: Luo, Hanjia, et al.
Publicado: (2023)

Identification of a Novel Di-D-Fructofuranose 1,2’:2,3’ Dianhydride (DFA III) Hydrolysis Enzyme from Arthrobacter aurescens SK8.001
por: Yu, Shuhuai, et al.
Publicado: (2015)

High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study
por: Su, Yanhong, et al.
Publicado: (2021)

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
por: Tokuda, Y, et al.
Publicado: (1999)

Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies
por: Krawczyk, Natalia, et al.
Publicado: (2022)

Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
por: LoRusso, Patricia, et al.
Publicado: (2013)

HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
por: Bueno Muiño, Coralia, et al.
Publicado: (2022)

Pharmacokinetics of escalating single‐dose administration of cannabidiol to cats
por: Rozental, Aaron J., et al.
Publicado: (2022)

De-escalation of adjuvant chemotherapy for HER2 negative breast cancer
por: Okines, Dr Alicia FC, et al.
Publicado: (2021)

Research on escalators used as evacuation stairs under fire scenarios
por: Zhang, Chunhua, et al.
Publicado: (2023)

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
por: Munster, Pamela, et al.
Publicado: (2018)

De-escalated radiotherapy for HER2-overexpressing breast cancer patients with 1-3 positive lymph nodes undergoing anti-HER2 targeted therapy
por: Liu, Jing, et al.
Publicado: (2023)

De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer
por: Tasoulis, Marios-Konstantinos, et al.
Publicado: (2022)

The Iron-Inflammation Axis in Early-Stage Triple-Negative Breast Cancer
por: Duan, Fangfang, et al.
Publicado: (2022)

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019)

Establishment and Validation of Prognostic Nomograms Based on Serum Copper Level for Patients With Early-Stage Triple-Negative Breast Cancer
por: Duan, Fangfang, et al.
Publicado: (2021)

A Novel Prognostic Model Based on the Serum Iron Level for Patients With Early-Stage Triple-Negative Breast Cancer
por: Hua, Xin, et al.
Publicado: (2021)

Real de-escalation or escalation in disguise?
por: Banys-Paluchowski, Maggie, et al.
Publicado: (2023)

Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer
por: Xue, Cong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t8up91m8trvu8utrk4j59di32i